AbbVie | Beneficio Operativo



Operating Profit Cambio Fecha
AbbVie USD -1490000000 5.32B 2024-12
Abbott USD 1.91B 41M 2024-12
ALKERMES USD 162.69M 57.93M 2024-12
Amgen USD 2.31B 182M 2024-12
AstraZeneca USD 2.04B 731M 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Eisai JPY 27.56B 13.14B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Gilead Sciences USD 2.45B 1.56B 2024-12
GlaxoSmithKline GBP 696M 507M 2024-12
J&J USD 3.89B 549M 2024-12
Medtronic USD 1.65B 51M 2025-01
Merck USD 4.3B 369M 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Pacira USD 24.7M 164.23M 2024-12
Perrigo USD 112.7M 37.4M 2024-12
Pfizer USD -409000000 5.57B 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Roche Holding CHF 4.39B 1.04B 2024-12
Sanofi EUR 4.09B 1.81B 2024-09
UCB EUR 163M 39M 2024-06
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
United Therapeutics USD 357.7M 14.6M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12
Zoetis USD 732M 142M 2024-12



AbbVie Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.